Lopinavir

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Peripheral neuropathy, Diarrhea, Marketing, Zidovudine, European Commission, Protease, Pharyngitis, INN, Immune system, Heartburn, HIV/AIDS, Fatigue, Saquinavir, Darunavir, ATC, Depression, Itch, Ritonavir, AIDS, International, Capsule, Cough, European, Headache, Disease, CD4, Ageing, Body surface area, Blood, Sore throat, Nausea, Rash, Language, Mouth, Abdominal pain, Dizziness, Flushing, Infection, Food, Indigestion, HIV, Tablet, Chronic pain, Reproduction, Back pain, Select, Committee, Patient, Dysgeusia, Risk management, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Lopinavir, CHMP, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Common, Diarrhea, Marketing, HIV-1, European Commission, Agency, Protease, HIV, INN, Immune system, Upper respiratory tract infection, ATC, Nelfinavir, Depression, EMA, AIDS, International, Capsule, European, Ageing, Nausea, Blood, Language, European Medicines Agency, Infection, Food, Ritonavir, Tablet, Reproduction, Select, Patient, Human, Liver disease, Anatomy, Medicine, IIA, Lopinavir, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Retrieved on: 
Tuesday, November 3, 2020
Chemistry, Organic compounds, Chemical compounds, HIV protease inhibitors, Ureas, Hepatotoxins, Clinical Pharmacology & Therapeutics, Lopinavir, Favipiravir, Remdesivir, Clinical Pharmacology: Advances and Applications, Ritonavir

CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Key Points: 
  • CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
  • We are honored to be sharing this peer-reviewed manuscript in an internationally acclaimed journal, said George Yeh, President of TLC.
  • CTS has a collection of clinical pharmacology research from various potential treatments such as remdesivir, favipiravir, and lopinavir/ritonavir.
  • Acknowledgment of our work by CTS further fortifies the soundness of our strategy of preferential delivery to the lungs.

Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published

Retrieved on: 
Wednesday, August 12, 2020
RTT, Health, Organic compounds, Chemical compounds, Chloroquine, Hydroxychloroquine, Lopinavir, Azithromycin, Ritonavir, Adverse drug reaction, COVID-19 drug development, COVID-19 drug repurposing research

In the study, TRHCs PPRDI first utilized TRHCs MedWise technology to determine each patients MedWise Risk Score (MRS), which is a predictive tool for adverse drug events (ADEs).

Key Points: 
  • In the study, TRHCs PPRDI first utilized TRHCs MedWise technology to determine each patients MedWise Risk Score (MRS), which is a predictive tool for adverse drug events (ADEs).
  • Next, five repurposed COVID-19 drugs (or drug combinations) were added, one at a time, to patient drug regimens.
  • The drug combinations included hydroxychloroquine, alone and in combination with azithromycin; chloroquine, alone and in combination with azithromycin; and lopinavir + ritonavir.
  • The results of this study validate the science behind our MedWise technology, states TRHC Chair and CEO Calvin H. Knowlton, Ph.D.